William R. Shaw - Feb 17, 2022 Form 4 Insider Report for EKSO BIONICS HOLDINGS, INC. (EKSO)

Role
Chief Commercial Officer
Signature
/s/ John F. Glenn, as attorney-in-fact
Stock symbol
EKSO
Transactions as of
Feb 17, 2022
Transactions value $
$0
Form type
4
Date filed
2/22/2022, 06:33 PM
Previous filing
Apr 7, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EKSO Common Stock Award $0 +17.9K +22.71% $0.00 96.9K Feb 17, 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares acquired pursuant to a restricted stock units award granted on March 3, 2021 that had both performance-based and time-based vesting conditions. The performance-based vesting conditions have been satisfied, and now the award is subject only to time-based vesting conditions. The award vests in three equal annual installments beginning on March 3, 2022.